CCP
CRSP icon

Clough Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

Clough Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
24,685
+1,685
+7% +$88.9K 0.11% 82
2025
Q4 		$1.21M Hold
23,000
– – 0.11% 89
2025
Q3 		$1.49M Buy
+23,000
New +$1.32M 0.13% 76
2025
Q1 		– Sell
-57,200
Closed -$2.25M – 115
2024
Q4 		$2.25M Buy
+57,200
New +$2.7M 0.26% 65
2024
Q3 		– Sell
-20,939
Closed -$1.13M – 136
2024
Q2 		$1.13M Buy
+20,939
New +$1.21M 0.12% 79
2024
Q1 		– Sell
-5,226
Closed -$327K – 133
2023
Q4 		$327K Buy
+5,226
New +$289K 0.04% 168
2023
Q3 		– Sell
-56,969
Closed -$3.2M – 215
2023
Q2 		$3.2M Sell
56,969
-65,131
-53% -$3.7M 0.32% 89
2023
Q1 		$5.52M Sell
122,100
-139,600
-53% -$6.78M 0.6% 62
2022
Q4 		$10.6M Sell
261,700
-153,067
-37% -$8.12M 1.08% 33
2022
Q3 		$27.1M Buy
414,767
+97,500
+31% +$7.07M 2.89% 8
2022
Q2 		$19.3M Buy
317,267
+111,160
+54% +$6.53M 2.39% 16
2022
Q1 		$12.9M Buy
206,107
+100,100
+94% +$6.29M 0.98% 41
2021
Q4 		$8.03M Sell
106,007
-35,300
-25% -$3.08M 0.54% 56
2021
Q3 		$15.8M Sell
141,307
-31,860
-18% -$4M 0.96% 43
2021
Q2 		$28M Sell
173,167
-13,810
-7% -$1.68M 1.52% 18
2021
Q1 		$22.8M Buy
186,977
+41,970
+29% +$6.34M 1.02% 38
2020
Q4 		$22.2M Sell
145,007
-121,820
-46% -$14.4M 1.58% 23
2020
Q3 		$22.3M Sell
266,827
-30,200
-10% -$2.68M 1.61% 20
2020
Q2 		$21.8M Hold
297,027
– – 2.14% 9
2020
Q1 		$12.6M Sell
297,027
-147,900
-33% -$7.64M 1.25% 27
2019
Q4 		$27.1M Sell
444,927
-34,876
-7% -$1.9M 2.31% 14
2019
Q3 		$19.7M Buy
479,803
+38,500
+9% +$1.84M 1.63% 18
2019
Q2 		$20.8M Sell
441,303
-138,963
-24% -$5.55M 2.04% 11
2019
Q1 		$20.7M Buy
580,266
+64,200
+12% +$2.22M 1.81% 18
2018
Q4 		$14.7M Buy
516,066
+178,335
+53% +$6.2M 1.73% 14
2018
Q3 		$15M Sell
337,731
-45,100
-12% -$2.36M 1.41% 21
2018
Q2 		$22.5M Sell
382,831
-177,400
-32% -$10.1M 2.01% 15
2018
Q1 		$25.6M Sell
560,231
-330,400
-37% -$13.6M 2.45% 10
2017
Q4 		$20.9M Buy
890,631
+110,700
+14% +$2.1M 1.74% 19
2017
Q3 		$13.9M Sell
779,931
-17,300
-2% -$314K 0.93% 35
2017
Q2 		$12.8M Sell
797,231
-27,633
-3% -$456K 0.89% 37
2017
Q1 		$17.9M Sell
824,864
-13,927
-2% -$273K 1.14% 27
2016
Q4 		$16.7M Buy
+838,791
New +$15.7M 1.11% 32

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Clough Capital Partners's CRSP Position: Q1 2026 in Review

Clough Capital Partners increased its CRISPR Therapeutics (CRSP) stake by 7.3% in Q1 2026, buying an estimated $88.9K and bringing the position to 24,685 shares worth $1.17M. The position accounts for 0.11% of the portfolio, ranked #82.

Clough Capital Partners first reported a position in CRSP in Q4 2016 and has held it in 33 quarters since. The position peaked at $28M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Clough Capital Partners held 24,685 shares of CRISPR Therapeutics worth $1.17M as of Q1 2026.
  • Clough Capital Partners bought 1,685 CRISPR Therapeutics shares in Q1 2026, an estimated $88.9K.
  • CRISPR Therapeutics made up 0.11% of Clough Capital Partners's portfolio in Q1 2026, its #82 holding.
  • Clough Capital Partners first reported a position in CRISPR Therapeutics in Q4 2016 and has held it in 33 quarters since.
  • Clough Capital Partners's CRISPR Therapeutics position peaked at $28M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Clough Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.